Universal Ibogaine Past Earnings Performance

Past criteria checks 0/6

Universal Ibogaine has been growing earnings at an average annual rate of 10.4%, while the Healthcare industry saw earnings growing at 5.8% annually. Revenues have been growing at an average rate of 61.2% per year.

Key information

10.4%

Earnings growth rate

59.8%

EPS growth rate

Healthcare Industry Growth15.7%
Revenue growth rate61.2%
Return on equity-100.2%
Net Margin-66.9%
Last Earnings Update30 Apr 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Universal Ibogaine makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:JC4 Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Apr 242-210
31 Jan 242-110
31 Oct 232-210
31 Jul 231-220
30 Apr 231-620
31 Jan 231-730
31 Oct 221-740
31 Jul 221-1050
30 Apr 221-850
31 Jan 221-850
31 Oct 210-750
31 Jul 210-440
30 Apr 210-640
31 Jul 200-620

Quality Earnings: JC4 is currently unprofitable.

Growing Profit Margin: JC4 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: JC4 is unprofitable, but has reduced losses over the past 5 years at a rate of 10.4% per year.

Accelerating Growth: Unable to compare JC4's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: JC4 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (30.9%).


Return on Equity

High ROE: JC4 has a negative Return on Equity (-100.24%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies